NCT06801236
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06801236
Title Phase 1 Study of ACE-232 to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Acerand Therapeutics (Hong Kong) Limited
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego, Moores Cancer Center RECRUITING La Jolla California 92093 United States Details
Moffitt Cancer Center, Tampa RECRUITING Tampa Florida 33612 United States Details
University of Maryland, Greenebaum Comprehensive Cancer Center RECRUITING Baltimore Maryland 21201 United States Details
Harvard Medical School-Massachusetts General Hospital RECRUITING Boston Massachusetts 02114 United States Details
M Health Fairview Clinics and Surgery Center RECRUITING Minneapolis Minnesota 55455 United States Details
Xcancer (Urology Cancer Center) WITHDRAWN Omaha Nebraska 68130 United States Details
Carolina Urologic Research Center RECRUITING Myrtle Beach South Carolina 29572 United States Details
Fred Hutchinson Cancer Research Center RECRUITING Seattle Washington 98109 United States Details
Beijing Gobroard Hospital NOT_YET_RECRUITING Beijing China 102200 China Details
Zhejiang Cancer Hospital NOT_YET_RECRUITING Hangzhou China 310022 China Details
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine NOT_YET_RECRUITING Shanghai China 200127 China Details
Henan Cancer Hospital NOT_YET_RECRUITING Zhengzhou China 450008 China Details
Fujian Cancer Hospital RECRUITING Fuzhou Fujian China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field